제약 분야 라이선싱 계약(2021-2026년)

Understand how pharmaceutical licensing deals are structured, valued and negotiated using intelligence from 2,299 real-world transactions.

Licensing Deals in Pharmaceuticals provides comprehensive intelligence on 2,299 licensing deals announced across the global pharmaceutical industry.

Licensing remains one of the most important mechanisms through which pharmaceutical companies access external innovation, monetize assets, expand development pipelines and secure rights to technologies and products.

The report examines how companies structure these transactions, which organizations are most active, where licensing activity is concentrated and what can be learned from disclosed financial terms and publicly available contract documents.

Rather than simply identifying transactions, the report provides a practical intelligence and benchmarking resource for teams seeking to understand what rights are being licensed, how responsibilities are divided, how financial consideration is structured and how comparable agreements have been negotiated in practice.

It is designed for business development, licensing, search and evaluation, corporate strategy, legal, alliance management and transaction teams involved in evaluating, structuring or negotiating pharmaceutical licensing agreements.

Understand the pharmaceutical licensing landscape

The report analyzes licensing dealmaking from 2021 to 2026, including:

• Trends in licensing dealmaking by year
• Phase of development at the time of partnering
• Industry sector
• Therapy area
• Technology type
• Most active licensing dealmakers
• Leading licensing deals by disclosed value
• Strategic reasons for entering licensing agreements
• How pharmaceutical licensing strategies are evolving
• This provides a clear view of where licensing activity is concentrated and which companies, technologies and therapeutic areas are attracting the greatest partnering attention.
• Understand how licensing agreements are structured
• Licensing agreements require careful allocation of rights, responsibilities, economics and future control of the licensed asset or technology.

The report provides intelligence to help users examine areas including:

• Rights granted or retained
• Exclusive and non-exclusive licenses
• Geographic and territorial rights
• Field-of-use restrictions
• Development responsibilities
• Regulatory responsibilities
• Manufacturing and supply arrangements
• Commercialization rights and obligations
• Intellectual property ownership and control
• Sublicensing rights
• Governance and decision-making
• Development and commercialization diligence
• Term and termination provisions
• Financial terms where disclosed
• These real-world examples provide useful reference points when evaluating potential licensing structures or preparing for negotiations.
• Benchmark licensing deal financials
• Financial structure is a critical component of pharmaceutical licensing.

The report provides access to disclosed financial information associated with individual licensing agreements, allowing users to investigate elements such as:

• Upfront payments
• Development milestones
• Regulatory milestones
• Commercial milestones
• Royalty arrangements
• Equity investments
• Research or development funding
• Other financial commitments where disclosed
• Leading licensing deals are also ranked by disclosed deal value, enabling users to identify significant precedent transactions and investigate their underlying structures.
• This intelligence can help place proposed transactions into the context of comparable real-world agreements and provide evidence to support deal preparation and negotiation.
• Identify leading licensing dealmakers
• The report profiles the Top 25 most active licensing dealmakers, providing insight into companies with a demonstrated appetite for pharmaceutical licensing transactions.

Individual transaction histories can help users understand:

• Which companies are actively licensing assets and technologies
• The therapeutic and technology areas attracting their interest
• The development stages at which they typically partner
• Previous transactions that may provide relevant comparables
• Potential partners for future licensing opportunities
• This makes the report particularly valuable for partner identification, search and evaluation and competitive intelligence.
• Learn from real-world licensing contracts
• Where publicly available, the report provides access to underlying licensing contract documents.

These agreements can reveal significantly more than headline announcements, allowing users to examine how companies have negotiated and documented important provisions including:

• Scope of license
• Exclusivity
• Territory and field
• Intellectual property rights
• Development obligations
• Sublicensing
• Manufacturing and commercialization rights
• Upfront and milestone payments
• Royalty provisions
• Termination and reversion rights
• For teams preparing for a licensing transaction, access to real agreement language provides valuable insight into how comparable provisions have been structured in practice.
• Comprehensive licensing deal directory
• The report includes a comprehensive directory of 2,299 pharmaceutical licensing deals, enabling users to identify transactions relevant to their own assets, technologies and partnering objectives.

Deals can be reviewed by:

• Company
• Therapy area
• Technology type
• Contract availability
• Individual transactions are linked to their underlying deal records, providing a route to further deal information and associated contract documentation where available.
• Who should use this report?
• Business Development and Licensing teams
• Identify comparable transactions, potential partners and relevant deal structures when preparing licensing strategies and negotiations.
• Search and Evaluation teams
• Identify companies with demonstrated interest in particular technologies, therapeutic areas and stages of development.
• Corporate and Portfolio Strategy teams
• Understand how pharmaceutical companies are using licensing to access innovation, build pipelines and expand into new areas.
• Legal and Transaction teams
• Review real agreement structures and publicly available contract language to support drafting, negotiation and due diligence.
• Alliance Management teams
• Understand how rights, responsibilities, governance and ongoing obligations have been structured across comparable licensing relationships.
• Competitive and Market Intelligence teams
• Track licensing activity by company, technology, therapy area and development phase to identify changing partnering priorities.
• Turn market-wide intelligence into company-specific insight
• For qualifying customers, Current Partnering can also provide a Customized Executive Partnering Briefing alongside the report.
• The briefing applies the underlying licensing intelligence to the customer's own business, assets, technologies or partnering objectives.
• Depending on requirements, this can include relevant comparable transactions, prospective licensing partners, competitor activity, deal structures, financial benchmarks, contract insights and other intelligence selected specifically for the client's situation.
• Request a sample or contact Current Partnering to discuss the report and whether a customized analysis can be provided for your organization.

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in licensing dealmaking

• 2.1. Introduction
• 2.2. Definition of licensing deal
• 2.3. Trends in licensing deals
  • 2.3.1. Licensing dealmaking by year
  • 2.3.2. Licensing dealmaking by phase of development
  • 2.3.3. Licensing dealmaking by industry sector
  • 2.3.4. Licensing dealmaking by therapy area
  • 2.3.5. Licensing dealmaking by technology type
  • 2.3.6. Licensing dealmaking by most active company
• 2.4. Reasons for entering into licensing partnering deals
• 2.5. The future of licensing deals

Chapter 3 - Overview of licensing deal structure

• 3.1. Introduction
• 3.2. Licensing agreement structure

Chapter 4 - Leading licensing deals

• 4.1. Introduction
• 4.2. Top licensing deals by value

Chapter 5 - Top 25 most active licensing dealmakers

• 5.1. Introduction
• 5.2. Top 25 most active licensing dealmakers

Chapter 6 - Licensing deals including contracts directory

• 6.1. Introduction
• 6.2. Licensing deals with contracts
• Deal directory
• Deal directory - licensing dealmaking by companies A-Z
• Deal directory - licensing dealmaking by therapy area
• Deal directory - licensing dealmaking by technology type
• About Biopharma Research
• Current Partnering
• Current Agreements
• Recent report titles from Current Partnering

TABLE OF FIGURES

• Figure 1: Definition of licensing
• Figure 2: Trends in licensing deal announcements
• Figure 3: Licensing deals signed at each phase of development
• Figure 4: Licensing deals by industry sector
• Figure 5: Licensing deals by therapy area
• Figure 6: Licensing deals by technology type
• Figure 7: Top 25 most active licensing dealmakers
• Figure 8: Top licensing deals by value
• Figure 9: Most active licensing dealmakers